Search Results

OBiO Technology Corp., Ltd. will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th.

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality and manufacturability.

Ori Biotech Ltd., a leader in cell and gene therapy manufacturing technology, announces the commercial launch of IRO®, a next-generation platform built specifically to overcome the current challenges in CGT manufacturing.

The intellectual property landscape for newer gene-editing technologies, like that for CRISPR-Cas9, remains unclear and hard to navigate.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems.

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced that it completed exclusive commercial licensing of a gene editing technology from the University of California Berkeley.

While ex vivo genome editing results in highly effective cell therapies, it can lead to off-target effects. Caribou Biosciences has come up with a novel approach for potentially more precise gene editing compared to all-RNA guides.

2seventy bio, Inc., announced the completion of an asset purchase agreement by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.